JJ
ZY

Johnson & Johnson’s Zymergen Inc. Common Stock ZY Stock Holding History

Johnson & Johnson’s Portfolio ZY Stock Details ZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-16,553
Closed -$218K – 27
2021
Q3 		$218K Buy
+16,553
New +$351K 0.02% 22

Other funds holding ZY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
TVPI
True Venture Partners IV Palo Alto, California $8.41M AUM 78.89% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
DCI
Data Collective II Palo Alto, California $8.44M AUM 11.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TSV
Two Sigma Ventures New York $9.61M AUM 58.41% 1-Year Est. Return

Johnson & Johnson's ZY Position: Q4 2021 in Review

Johnson & Johnson sold out of Zymergen Inc. Common Stock (ZY) in Q4 2021, closing a stake of 16,553 shares — an estimated $218K sold.

Johnson & Johnson first reported a position in ZY in Q3 2021 and held it in 1 quarter. The position peaked at $218K in Q3 2021. 91 funds tracked by Wall St. Rank hold ZY as of Q4 2021.

  • Johnson & Johnson reported no remaining Zymergen Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Johnson & Johnson sold 16,553 Zymergen Inc. Common Stock shares in Q4 2021, an estimated $218K.
  • Johnson & Johnson first reported a position in Zymergen Inc. Common Stock in Q3 2021 and held it in 1 quarter.
  • Johnson & Johnson's Zymergen Inc. Common Stock position peaked at $218K in Q3 2021.
  • 91 funds tracked by Wall St. Rank held Zymergen Inc. Common Stock as of Q4 2021.

Based on Johnson & Johnson's 13F filing for Q4 2021, filed 14 Feb 2022.